Bone-resorbing cells in multiple myeloma: Osteoclasts, myeloma cell polykaryons, or both?

Oncologist

Volumn 14, Issue 3, 2009, Pages 264-275

  Silvestris, Franco ^a,b   Ciavarella, Sabino ^a   De Matteo, Monica ^a   Tucci, Marco ^a   Dammacco, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

^b DIMO   (Italy)

Author keywords

Multiple myeloma; Myeloma bone disease; Osteoclasts; Polykaryons

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ACIDIFICATION; ARTICLE; BONE ATROPHY; BONE DISEASE; BONE MATRIX; CELL ACTIVITY; CELL COUNT; CHROMOSOME TRANSLOCATION; DISEASE SEVERITY; HUMAN; MORBIDITY; MULTINUCLEAR CELL; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

BONE RESORPTION; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; PLASMA CELLS;

EID: 63849262026     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2008-0087     Document Type: Article

References (73)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997;336: 1657-1664.
2. Oyajobi BO, Mundy GR. Pathophysiology of myeloma bone disease. In: Gahrton G, Durie BGM, Samson DM, eds. Multiple Myeloma and Related Disorders. London: Arnold, 2004:74-88.
3. Mundy GR. Myeloma bone disease. Eur J Cancer 1998;34:246-251.
4. Djulbegovic B, Wheatley K, Ross J et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev 2002;(3):CD003188.
5. Caligaris-Cappio F, Bergui L, Gregoretti MG et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood 1991;77: 2688-2693.
6. Terpos E, Politou M, Rahemtulla A. New insights into the pathophysiology
7. and management of bone disease in multiple myeloma. Br J Haematol 2003;123:758-769.
8. Roodman GD. Role ofthe bone marrow microenvironmentin multiple myeloma. J Bone Miner Res 2002;17:1921-1925.
9. Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition. Blood 2006;108:3992-3996.
10. Bataille R, Chappard D, Alexandre C et al. Importance of quantitative histology of bone changes in monoclonal gammopathy. Br J Cancer 1986;53: 805-810.
11. Terpos E, Politou M, Rahemtulla A. The role of markers of bone remodeling in multiple myeloma. Blood Rev 2005;19:125-142.
12. Silvestris F, Lombardi L, De Matteo M et al. Myeloma bone disease: Patho-genetic mechanisms and clinical assessment. Leuk Res 2007;31:129 -138.
13. Farrugia AN, Atkins GJ, To LB et al. Receptor activator of nuclear factor kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-5445.
14. Lai FP, Cole-Sinclair M, Cheng WJ et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblastpathwayofosteoclaststimulation. Br J Haematol 2004;126:192-201.
15. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350: 1655-1664.
16. McDonald DF, Schofield BH, Prezioso EM et al. Direct bone resorbing activity of murine myeloma cells. Cancer Lett 1983;19:119-124.
17. Andersen TL, Boissy P, Sondergaard TE et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: Anew type of cancer-host partnership? J Pathol 2007;211:10-17.
18. Calvani N, Cafforio P, Silvestris F et al. Functional osteoclast-like transformation of cultured human myeloma cell lines. Br J Haematol 2005;130: 926-938.
19. Zhang YH, Heulsmann A, Tondravi MM et al. Tumor necrosis factor-alpha (TNF) stimulates RANKL-induced osteoclastogenesis viacoupling ofTNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276: 563-568.
20. Kitaura H, Zhou P, Kim HJ et al. M-CSF mediates TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-3427.
21. Sezer O, Heider U, Zavrski I et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098.
22. Standal T, Seidel C, Hjertner 0 et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002;100:3002-3007.
23. Seidel C, Hjertner 0, Abildgaard N et al.; Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269-2271.
24. Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator ofnuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: Proposal fora novel prognostic index. Blood 2003;102:1064-1069.
25. Politou M, Terpos E, Anagnostopoulos A et al. Role ofreceptoractivatorof nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 2004;126:686-689.
26. Silvestris F, Cafforio P, Calvani N et al. Impaired osteoblastogenesis in myeloma bone disease: Role of upregulated apoptosis by cytokines and malignant plasma cells. Br J Haematol 2004;126:475-486.
27. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-2494.
28. Hjertner O, Torgersen ML, Seidel C et al. Hepatocyte growthfactor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease. Blood 1999;94:3883-3888.
29. Feliers D, WoodruffK, Abboud S. Potential role ofinsulin-like growthfac- tor binding protein-4 in the uncoupling of bone turnover in multiple myeloma. Br J Haematol 1999;104:715-722.
30. Epstein J, Walker R. Myeloma and bone disease: "The dangerous tango."Clin Adv Hematol Oncol 2006;4:300-306.
31. Rasmussen H, Bordier P. The cellular basis of metabolic bone disease. N Engl J Med 1973;289:25-32.
32. Walker DG. Bone resorption restored in osteopetrotic mice by transplants of normal bone marrow and spleen cells. Science 1975;190:784-785.
33. Takahashi N, Yamana H, Yoshiki S et al. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 1988;122:1373-1382.
34. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997;89: 309 -319.
35. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]- related activation-induced cytokine), a new TNF family member predominantly expressed inTcells, is a dendriticcell-specificsurvival factor. J Exp Med 1997;186:2075-2080.
36. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
37. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-342.
38. Yoshida H, Hayashi SI, Kunisada T et al. The murine mutation osteopetro- sis is in the coding region of the macrophage colony stimulating factor gene. Nature 1990;345:442-444.
39. Mocsai A, Humphrey MB, Van Ziffle JA et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRy) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad SciUSA 2004;101:6158-6163.
40. KogaT, Inui M, Inoue K et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428: 758 -763.
41. Fuller K, Murphy C, Kirstein B et al. TNFalpha potently activates oste- oclasts, througha direct action independentofand strongly synergistic with RANKL. Endocrinology 2002;143:1108 -1118.
42. Lam J, Takeshita S, Barker JE et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000;106:1481-1488.
43. Faccio R, Novack DV, Zallone A et al. Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by β3 integrin. J Cell Biol 2003;162:499-509.
44. McHugh KP, Hodivala-Dilke K, Zheng MH et al. Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest 2000; 105:433-440.
45. Yagi M, Miyamoto T, Toyama Y et al. Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells. J Bone Miner Metab 2006; 24:355-358.
46. Aggarwal R, Ghobrial IM, Roodman GD. Chemokines in multiple myeloma. Exp Hematol 2006;34:1289-1295.
47. Yagi M, Ninomiya K, Fujita N et al. Induction of DC-STAMP by alternative activation and downstream signalling mechanisms. J Bone Miner Res 2007;22:992-1001.
48. Yagi M, Miyamoto T, Sawatani Y et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202: 345-351.
49. Terpos E, Politou M, Szydlo R et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1α) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123: 106 -109.
50. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteo-immunology. J Mol Med 2005;83:170-179.
51. Yaccoby S, WezemanMJ, Zangari M et al. Inhibitory effects ofosteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica 2006;91:192-199.
52. Ghevaert C, Fournier M, Bernardi F et al. Non-secretory multiple myeloma with multinucleated giant plasma cells. Leuk Lymphoma 1997;27:185- 189.
53. Zukerberg LR, Ferry JA, Conlon M et al. Plasma cell myeloma with cleaved, multilobated, and monocytoid nuclei. Am J Clin Pathol 1990;93: 657-661.
54. Kurabayashi H, Miyawaki S, Murakami H et al. Ultrastructure of multinucleated giant myeloma cells: Report of one case. Am J Hematol 1989;31: 284-285.
55. Buss DH, Reynolds GD, Cooper MR. Multiple myeloma associated with multilobated plasma cell nuclei. Virchows Arch B Cell Pathol Incl Mol Pathol 1988;55:287-292.
56. Durie BGM, Grogan TM, Spier C et al. Myelomonocytic myeloma cell line (LB 84-1). Blood 1989;73:770-776.
57. Duperray C, Klein B, Durie BGM et al. Phenotypic analysis of human myeloma cell lines. Blood 1989;73:566-572.
58. Liu S, Otsuyama K, Ma Z et al. Induction of multilineage markers in human myeloma cells and their down-regulation by interleukin 6. Int J Hematol 2007;85:49-58.
59. Silvestris F, Cafforio P, Tucci M et al. Negative regulation of erythroblast maturation by Fas-L( + )/TRAIL( +) highly malignant plasma cells: A major pathogenetic mechanism of anemia in multiple myeloma. Blood 2002; 99:1305-1313.
60. Faust J, Lacey DL, Hunt P et al. Osteoclast markers accumulate on cells developing from human peripheral blood mononuclear precursors. J Cell Biochem 1999;72:67-80.
61. Silvestris F, Cafforio P, De Matteo M et al. Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. Leuk Res 2008;32:611-623.
62. Silvestris F, Cafforio P, Calvani N et al. In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. Leuk Lymphoma 2006;47:1921-1931.
63. Eilon G, Mundy GR. Directresorption of bone by human breast cancer cells in vitro. Nature 1978;276:726-728.
64. Sanchez-Sweatman OH, Lee J, Orr FW et al. Direct osteolysis induced by metastatic murine melanoma cells: Role of matrix metalloproteinases. Eur J Cancer 1997;33:918-925.
65. Roodman GD. Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 1997;80:1557-1563.
66. De Leenheer E, Mueller GS, Vanderkerken K et al. Evidence of a role for RANKL in the development of myeloma bone disease. Curr Opin Pharmacol 2004;4:340-346.
67. PiperK, Boyde A, Jones SJ. The relationshipbetweenthe numberofnuclei of an osteoclast and its resorptive capability in vitro. Anat Embryol (Berl) 1992;186:291-299.
68. Lees RL, Sabharwal VK, Heersche JNM. Resorptive state and cell size influence intracellular pH regulation in rabbit osteoclasts cultured on collagen-hydroxyapatite films. Bone 2001;28:187-194.
69. Xie HF, Ye M, Feng R et al. Stepwise reprogramming of B cells into mac-rophages. Cell 2004;117:663-676.
70. Breitkreutz I, Raab MS, Vallet S et al. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol 2007;139:55-63.
71. Lombardi L, Tucci L, Quatraro C et al. AlphaVBeta3 + (AvB3) adhesion molecule drives the osteoclast (OC)-like functional differentiation of myeloma cells. Presented at the XI International Myeloma Workshop, Kos Island, Greece, June 25-30, 2007.
72. Busund LTR, Killie MK, Bartnes K et al. Spontaneously formed tumori- genic hybrids of Meth A sarcoma cells and macrophages in vivo. Int J Cancer 2003;106:153-159.
73. Grano M, Colucci S, De Bellis M et al. New model for bone resorption study in vitro: Human osteoclast-like cells from giant cell tumors of bone. J Bone Miner Res 1994;9:1013-1020.